CoChat
Sign Up
Cited by 535

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Progress in microRNA delivery

Zhang, Yu, Wang, Zaijie, Gemeinhart, Richard A.·2013·Journal of Controlled Release
DOI 10.1016/j.jconrel.2013.09.015PMC PMC3891846
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2013.09.015

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 172

  1. Yan, 2012, The research strategies for probing the function of long noncoding RNAs, Genomics, 99, 76, 10.1016/j.ygeno.2011.12.002 · DOI
  2. Wery, 2011, Noncoding RNAs in gene regulation, Wiley Interdiscip. Rev. Syst. Biol. Med., 3, 728, 10.1002/wsbm.148 · DOI
  3. Choudhuri, 2010, Small noncoding RNAs: biogenesis, function, and emerging significance in toxicology, J. Biochem. Mol. Toxicol., 24, 195, 10.1002/jbt.20325 · DOI
  4. Robinson, 2004, RNAi therapeutics: how likely, how soon?, PLoS Biol., 2, E28, 10.1371/journal.pbio.0020028 · DOI
  5. Pasquinelli, 2000, Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA, Nature, 408, 86, 10.1038/35040556 · DOI
  6. Reinhart, 2000, The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans, Nature, 403, 901, 10.1038/35002607 · DOI
  7. Calin, 2002, Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. U. S. A., 99, 15524, 10.1073/pnas.242606799 · DOI · Paper page
  8. Li, 2013, miRNA regulatory variation in human evolution, Trends Genet., 29, 116, 10.1016/j.tig.2012.10.008 · DOI
  9. Lima, 2011, MicroRNA regulation of core apoptosis pathways in cancer, Eur. J. Cancer, 47, 163, 10.1016/j.ejca.2010.11.005 · DOI
  10. Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
  11. He, 2004, MicroRNAs: small RNAs with a big role in gene regulation, Nat. Rev. Genet., 5, 522, 10.1038/nrg1379 · DOI · Paper page
  12. Bohnsack, 2004, 10, 185
  13. Yi, 2003, Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs, Genes Dev., 17, 3011, 10.1101/gad.1158803 · DOI
  14. Lee, 2003, The nuclear RNase III Drosha initiates microRNA processing, Nature, 425, 415, 10.1038/nature01957 · DOI
  15. Lim, 2005, Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs, Nature, 433, 769, 10.1038/nature03315 · DOI · Paper page
  16. Olsen, 1999, The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation, Dev. Biol., 216, 671, 10.1006/dbio.1999.9523 · DOI · Paper page
  17. Doench, 2003, siRNAs can function as miRNAs, Genes Dev., 17, 438, 10.1101/gad.1064703 · DOI
  18. Ebert, 2007, MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells, Nat. Methods, 4, 721, 10.1038/nmeth1079 · DOI · Paper page
  19. Vasudevan, 2007, Switching from repression to activation: microRNAs can up-regulate translation, Science, 318, 1931, 10.1126/science.1149460 · DOI
  20. Guo, 2010, Mammalian microRNAs predominantly act to decrease target mRNA levels, Nature, 466, 835, 10.1038/nature09267 · DOI · Paper page
  21. Gallo, 2012, The majority of microRNAs detectable in serum and saliva is concentrated in exosomes, PLoS One, 7, e30679, 10.1371/journal.pone.0030679 · DOI · Paper page
  22. Li, 2006, Small dsRNAs induce transcriptional activation in human cells, Proc. Natl. Acad. Sci. U. S. A., 103, 17337, 10.1073/pnas.0607015103 · DOI
  23. Wang, 2011, The long arm of long noncoding RNAs: roles as sensors regulating gene transcriptional programs, Cold Spring Harb. Perspect. Biol., 3, a003756, 10.1101/cshperspect.a003756 · DOI
  24. Holz-Schietinger, 2012, RNA modulation of the human DNA methyltransferase 3A, Nucleic Acids Res., 40, 8550, 10.1093/nar/gks537 · DOI
  25. Bernstein, 2005, RNA meets chromatin, Genes Dev., 19, 1635, 10.1101/gad.1324305 · DOI
  26. Jeffries, 2011, Nuclear and cytoplasmic localization of neural stem cell microRNAs, RNA, 17, 675, 10.1261/rna.2006511 · DOI
  27. Kim, 2008, MicroRNA-directed transcriptional gene silencing in mammalian cells, Proc. Natl. Acad. Sci. U. S. A., 105, 16230, 10.1073/pnas.0808830105 · DOI
  28. Younger, 2011, Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters, Nucleic Acids Res., 39, 5682, 10.1093/nar/gkr155 · DOI
  29. Tomikawa, 2011, Single-stranded noncoding RNAs mediate local epigenetic alterations at gene promoters in rat cell lines, J. Biol. Chem., 286, 34788, 10.1074/jbc.M111.275750 · DOI
  30. Jopling, 2005, Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA, Science, 309, 1577, 10.1126/science.1113329 · DOI
  31. Stanczyk, 2008, Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis, Arthritis Rheum., 58, 1001, 10.1002/art.23386 · DOI
  32. Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702 · DOI
  33. Tatsuguchi, 2007, Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy, J. Mol. Cell. Cardiol., 42, 1137, 10.1016/j.yjmcc.2007.04.004 · DOI
  34. Jeyaseelan, 2007, MicroRNAs as therapeutic targets in human diseases, Expert Opin. Ther. Targets, 11, 1119, 10.1517/14728222.11.8.1119 · DOI
  35. Murakami, 2006, Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues, Oncogene, 25, 2537, 10.1038/sj.onc.1209283 · DOI
  36. Nelson, 2004, Microarray-based, high-throughput gene expression profiling of microRNAs, Nat. Methods, 1, 155, 10.1038/nmeth717 · DOI
  37. Lennox, 2011, Chemical modification and design of anti-miRNA oligonucleotides, Gene Ther., 18, 1111, 10.1038/gt.2011.100 · DOI
  38. Lennox, 2010, A direct comparison of anti-microRNA oligonucleotide potency, Pharm. Res., 27, 1788, 10.1007/s11095-010-0156-0 · DOI
  39. Czauderna, 2003, Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells, Nucleic Acids Res., 31, 2705, 10.1093/nar/gkg393 · DOI
  40. Cook, 1991, Medicinal chemistry of antisense oligonucleotides—future opportunities, Anticancer Drug Des., 6, 585
  41. Krutzfeldt, 2007, Specificity, duplex degradation and subcellular localization of antagomirs, Nucleic Acids Res., 35, 2885, 10.1093/nar/gkm024 · DOI
  42. Crooke, 1996, Pharmacokinetic properties of several novel oligonucleotide analogs in mice, J. Pharmacol. Exp. Ther., 277, 923
  43. Yoo, 2004, 2′-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro, Nucleic Acids Res., 32, 2008, 10.1093/nar/gkh516 · DOI
  44. Wahlestedt, 2000, Potent and nontoxic antisense oligonucleotides containing locked nucleic acids, Proc. Natl. Acad. Sci. U. S. A., 97, 5633, 10.1073/pnas.97.10.5633 · DOI · Paper page
  45. Hyrup, 1996, Peptide nucleic acids (PNA): synthesis, properties and potential applications, Bioorg. Med. Chem., 4, 5, 10.1016/0968-0896(95)00171-9 · DOI
  46. Pallan, 2011, Unexpected origins of the enhanced pairing affinity of 2′-fluoro-modified RNA, Nucleic Acids Res., 39, 3482, 10.1093/nar/gkq1270 · DOI
  47. Akhtar, 2000, The delivery of antisense therapeutics, Adv. Drug Deliv. Rev., 44, 3, 10.1016/S0169-409X(00)00080-6 · DOI
  48. Behlke, 2008, Chemical modification of siRNAs for in vivo use, Oligonucleotides, 18
  49. Manoharan, 2004, RNA interference and chemically modified small interfering RNAs, Curr. Opin. Chem. Biol., 8, 570, 10.1016/j.cbpa.2004.10.007 · DOI
  50. Corey, 2007, Chemical modification: the key to clinical application of RNA interference?, J. Clin. Invest., 117, 3615, 10.1172/JCI33483 · DOI
  51. Campbell, 1990, Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid, J. Biochem. Biophys. Methods, 20, 259, 10.1016/0165-022X(90)90084-P · DOI
  52. Patil, 2000, Influence of divalent cations on the conformation of phosphorothioate oligodeoxynucleotides: a circular dichroism study, Nucleic Acids Res., 28, 2439, 10.1093/nar/28.12.2439 · DOI
  53. Prakash, 2008, Comparing in vitro and in vivo activity of 2′-O-[2-(methylamino)-2-oxoethyl]- and 2′-O-methoxyethyl-modified antisense oligonucleotides, J. Med. Chem., 51, 2766, 10.1021/jm701537z · DOI
  54. Elmen, 2008, LNA-mediated microRNA silencing in non-human primates, Nature, 452, 896-U810, 10.1038/nature06783 · DOI · Paper page
  55. Lanford, 2010, Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection, Science, 327, 198, 10.1126/science.1178178 · DOI · Paper page
  56. Janssen, 2013, Treatment of HCV Infection by targeting MicroRNA, N. Engl. J. Med., 368, 1685, 10.1056/NEJMoa1209026 · DOI
  57. Fabani, 2010, Efficient inhibition of miR-155 function in vivo by peptide nucleic acids, Nucleic Acids Res., 38, 4466, 10.1093/nar/gkq160 · DOI
  58. Fabani, 2008, 14, 336
  59. Kole, 2012, RNA therapeutics: beyond RNA interference and antisense oligonucleotides, Nat. Rev. Drug Discov., 11, 125, 10.1038/nrd3625 · DOI · Paper page
  60. Juliano, 2012, Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides, Bioconjug. Chem., 23, 147, 10.1021/bc200377d · DOI · Paper page
  61. Ma, 2010, miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis, Nat. Cell Biol., 12, 247, 10.1038/ncb2024 · DOI
  62. Garzon, 2010, Targeting microRNAs in cancer: rationale, strategies and challenges, Nat. Rev. Drug Discov., 9, 775, 10.1038/nrd3179 · DOI
  63. Choi, 2007, Target protectors reveal dampening and balancing of nodal agonist and antagonist by miR-430, Science, 318, 271, 10.1126/science.1147535 · DOI
  64. Bader, 2011, Developing therapeutic microRNAs for cancer, Gene Ther., 18, 1121, 10.1038/gt.2011.79 · DOI
  65. Li, 2011, MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma, J. Biol. Chem., 286, 36677, 10.1074/jbc.M111.270561 · DOI
  66. Terasawa, 2011, Synthetic pre-miRNA-based shRNA as potent RNAi triggers, J. Nucleic Acids, 2011, 131579, 10.4061/2011/131579 · DOI
  67. Kim, 2009, Efficient siRNA delivery with non-viral polymeric vehicles, Pharm. Res., 26, 657, 10.1007/s11095-008-9774-1 · DOI
  68. Khatri, 2012, In vivo delivery aspects of miRNA, shRNA and siRNA, Crit. Rev. Ther. Drug Carrier Syst., 29, 487, 10.1615/CritRevTherDrugCarrierSyst.v29.i6.20 · DOI
  69. Pereira, 2013, Delivering the promise of miRNA cancer therapeutics, Drug Discov. Today, 18, 282, 10.1016/j.drudis.2012.10.002 · DOI
  70. Czech, 2011, RNAi-based therapeutic strategies for metabolic disease, Nat. Rev. Endocrinol., 7, 473, 10.1038/nrendo.2011.57 · DOI
  71. Park, 2006, Current status of polymeric gene delivery systems, Adv. Drug Deliv. Rev., 58, 467, 10.1016/j.addr.2006.03.007 · DOI
  72. Harris, 2010, Tissue-specific gene delivery via nanoparticle coating, Biomaterials, 31, 998, 10.1016/j.biomaterials.2009.10.012 · DOI
  73. Wood, 2008, Tumor-targeted gene delivery using molecularly engineered hybrid polymers functionalized with a tumor-homing peptide, Bioconjug. Chem., 19, 403, 10.1021/bc700408r · DOI
  74. Tseng, 2009, Lipid-based systemic delivery of siRNA, Adv. Drug Deliv. Rev., 61, 721, 10.1016/j.addr.2009.03.003 · DOI
  75. Elmen, 2008, Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver, Nucleic Acids Res., 36, 1153, 10.1093/nar/gkm1113 · DOI
  76. Liu, 2012, Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by an MUC1 aptamer-let-7i chimera, Cancer Invest., 30, 577, 10.3109/07357907.2012.707265 · DOI
  77. Wu, 2011, MicroRNA delivery by cationic lipoplexes for lung cancer therapy, Mol. Pharm., 8, 1381, 10.1021/mp2002076 · DOI
  78. Craig, 2012, Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo, Leukemia, 26, 2421, 10.1038/leu.2012.110 · DOI
  79. Trang, 2011, Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice, Mol. Ther., 19, 1116, 10.1038/mt.2011.48 · DOI
  80. Akao, 2010, Role of anti-oncomirs miR-143 and -145 in human colorectal tumors, Cancer Gene Ther., 17, 398, 10.1038/cgt.2009.88 · DOI
  81. Akinc, 2008, A combinatorial library of lipid-like materials for delivery of RNAi therapeutics, Nat. Biotechnol., 26, 561, 10.1038/nbt1402 · DOI · Paper page
  82. Piao, 2012, Lipid-based nanoparticle delivery of pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma, Mol. Ther., 20, 1261, 10.1038/mt.2012.67 · DOI
  83. Chen, 2010, Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy, Mol. Ther., 18, 1650, 10.1038/mt.2010.136 · DOI
  84. Liu, 2011, Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles, Mol. Pharm., 8, 250, 10.1021/mp100315q · DOI
  85. Su, 2011, Silencing microRNA by interfering nanoparticles in mice, Nucleic Acids Res., 39, e38, 10.1093/nar/gkq1307 · DOI
  86. Rai, 2011, Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells, Mol. Cancer Ther., 10, 1720, 10.1158/1535-7163.MCT-11-0220 · DOI
  87. Shi, 2013, Systemic delivery of microRNA-34a for cancer stem cell therapy, Angew. Chem., 52, 3901, 10.1002/anie.201208077 · DOI
  88. Ibrahim, 2011, MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma, Cancer Res., 71, 5214, 10.1158/0008-5472.CAN-10-4645 · DOI
  89. Chiou, 2012, Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma, J. Control. Release, 159, 240, 10.1016/j.jconrel.2012.01.014 · DOI
  90. Hwang do, 2011, A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA, Biomaterials, 32, 4968, 10.1016/j.biomaterials.2011.03.047 · DOI
  91. Ren, 2010, MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol, BMC Cancer, 10, 27, 10.1186/1471-2407-10-27 · DOI
  92. Ren, 2010, Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro, J. Biomater. Sci. Polym. Ed., 21, 303, 10.1163/156856209X415828 · DOI
  93. Cheng, 2012, Polymer nanoparticle-mediated delivery of MicroRNA inhibition and alternative splicing, Mol. Pharm., 9, 1481, 10.1021/mp300081s · DOI
  94. Babar, 2012, Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma, Proc. Natl. Acad. Sci. U. S. A., 109, E1695, 10.1073/pnas.1201516109 · DOI
  95. Tazawa, 2007, Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells, Proc. Natl. Acad. Sci. U. S. A., 104, 15472, 10.1073/pnas.0707351104 · DOI
  96. Matsuyama, 2011, miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma, Blood, 118, 6881, 10.1182/blood-2011-05-354654 · DOI
  97. Takeshita, 2010, Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes, Mol. Ther. J. Am. Soc. Gene Ther., 18, 181, 10.1038/mt.2009.207 · DOI
  98. Ohno, 2013, Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells, Mol. Ther., 21, 185, 10.1038/mt.2012.180 · DOI · Paper page
  99. Tivnan, 2012, Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD(2) coated nanoparticles, PLoS One, 7, e38129, 10.1371/journal.pone.0038129 · DOI
  100. Yigit, 2013, Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis, Oncogene, 32, 1530, 10.1038/onc.2012.173 · DOI
  101. Medina, 2004, Targeted liposomal drug delivery in cancer, Curr. Pharm. Des., 10, 2981, 10.2174/1381612043383467 · DOI
  102. Ando, 2013, Development of a miR-92a delivery system for anti-angiogenesis-based cancer therapy, J. Gene Med., 15, 20, 10.1002/jgm.2690 · DOI
  103. Baigude, 2007, Design and creation of new nanomaterials for therapeutic RNAi, ACS Chem. Biol., 2, 237, 10.1021/cb7000582 · DOI
  104. Boussif, 1995, A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine, Proc. Natl. Acad. Sci. U. S. A., 92, 10.1073/pnas.92.16.7297 · DOI
  105. de Fougerolles, 2007, Interfering with disease: a progress report on siRNA-based therapeutics, Nat. Rev. Drug Discov., 6, 443, 10.1038/nrd2310 · DOI
  106. Yang, 2012, Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI, Biomaterials, 33, 1462, 10.1016/j.biomaterials.2011.10.071 · DOI
  107. Maiorano, 2009, Promotion of embryonic cortico-cerebral neuronogenesis by miR-124, Neural Dev., 4, 40, 10.1186/1749-8104-4-40 · DOI · Paper page
  108. Hu, 2013, Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model, Biomaterials, 34, 2265, 10.1016/j.biomaterials.2012.12.016 · DOI
  109. Dutta, 2010, Dendrimer nanocarriers as versatile vectors in gene delivery, Nanomedicine, 6, 25, 10.1016/j.nano.2009.05.005 · DOI
  110. Hong, 2004, Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: Hole formation and the relation to transport, Bioconjug. Chem., 15, 774, 10.1021/bc049962b · DOI
  111. Kulkarni, 1971, Biodegradable poly(lactic acid) polymers, J. Biomed. Mater. Res., 5, 169, 10.1002/jbm.820050305 · DOI
  112. Blum, 2008, High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine, J. Control. Release, 129, 66, 10.1016/j.jconrel.2008.04.002 · DOI
  113. Ramanlal Chaudhari, 2012, Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel, J. Control. Release, 158, 470, 10.1016/j.jconrel.2011.11.020 · DOI
  114. Uchegbu, 2006, Pharmaceutical nanotechnology: polymeric vesicles for drug and gene delivery, Expert Opin. Drug Deliv., 3, 629, 10.1517/17425247.3.5.629 · DOI
  115. Maeda, 2001, The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting, Adv. Enzym. Regul., 41, 189, 10.1016/S0065-2571(00)00013-3 · DOI · Paper page
  116. Gibbings, 2010, Control of RNA silencing and localization by endolysosomes, Trends Cell Biol., 20, 491, 10.1016/j.tcb.2010.06.001 · DOI
  117. Gibbings, 2009, Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity, Nat. Cell Biol., 11, 1143, 10.1038/ncb1929 · DOI
  118. Gomes, 2013, Efficient pro-survival/angiogenic miRNA delivery by an MRI-detectable nanomaterial, ACS Nano, 7, 3362, 10.1021/nn400171w · DOI
  119. Dang, 2006, Natural polymers for gene delivery and tissue engineering, Adv. Drug Deliv. Rev., 58, 487, 10.1016/j.addr.2006.03.001 · DOI · Paper page
  120. Mahat, 1999, Peptide-based gene delivery, Curr. Opin. Mol. Ther., 1, 226
  121. Stenzel, 1974, Collagen as a biomaterial, Annu. Rev. Biophys. Bioeng., 3, 231, 10.1146/annurev.bb.03.060174.001311 · DOI
  122. Minakuchi, 2004, Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo, Nucleic Acids Res., 32, e109, 10.1093/nar/gnh093 · DOI
  123. Suh, 2013, Peptide-mediated intracellular delivery of miRNA-29b for osteogenic stem cell differentiation, Biomaterials, 34, 4347, 10.1016/j.biomaterials.2013.02.039 · DOI
  124. Crew, 2012, MicroRNA conjugated gold nanoparticles and cell transfection, Anal. Chem., 84, 26, 10.1021/ac202749p · DOI
  125. Ghosh, 2013, A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells, Biomaterials, 34, 807, 10.1016/j.biomaterials.2012.10.023 · DOI
  126. Bitar, 2012, Silica-based nanoparticles for biomedical applications, Drug Discov. Today, 17, 1147, 10.1016/j.drudis.2012.06.014 · DOI
  127. Hoffman, 2008, The origins and evolution of controlled drug delivery systems, J. Control. Release, 132, 153, 10.1016/j.jconrel.2008.08.012 · DOI
  128. Krieg, 2011, Is RNAi dead?, Mol. Ther., 19, 1001, 10.1038/mt.2011.94 · DOI
  129. Ledford, 2010, Drug giants turn their backs on RNA interference, Nature, 468, 487, 10.1038/468487a · DOI
  130. Guo, 2013, Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer?, Trends Mol. Med., 19, 250, 10.1016/j.molmed.2013.02.002 · DOI
  131. Eifler, 2011, Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study, Methods Mol. Biol., 726, 325, 10.1007/978-1-61779-052-2_21 · DOI
  132. Scholz, 2012, Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers, J. Control. Release, 161, 554, 10.1016/j.jconrel.2011.11.014 · DOI
  133. Haussecker, 2012, The business of RNAi therapeutics in 2012, Mol. Ther. Nucleic Acids, 1, e8, 10.1038/mtna.2011.9 · DOI
  134. Ruoslahti, 2010, Targeting of drugs and nanoparticles to tumors, J. Cell Biol., 188, 759, 10.1083/jcb.200910104 · DOI
  135. Oberbauer, 1995, Renal uptake of an 18-mer phosphorothioate oligonucleotide, Kidney Int., 48, 1226, 10.1038/ki.1995.406 · DOI
  136. Veronese, 2001, Peptide and protein PEGylation: a review of problems and solutions, Biomaterials, 22, 405, 10.1016/S0142-9612(00)00193-9 · DOI
  137. Veronese, 2005, PEGylation, successful approach to drug delivery, Drug Discov. Today, 10, 1451, 10.1016/S1359-6446(05)03575-0 · DOI
  138. Friman, 1993, Hepatic excretion and metabolism of polyethylene glycols and mannitol in the cat, J. Hepatol., 17, 48, 10.1016/S0168-8278(05)80520-3 · DOI
  139. Dobrovolskaia, 2007, Immunological properties of engineered nanomaterials, Nat. Nanotechnol., 2, 469, 10.1038/nnano.2007.223 · DOI · Paper page
  140. Rao, 2008, Shedding light on tumors using nanoparticles, ACS Nano, 2, 1984, 10.1021/nn800669n · DOI
  141. Moghimi, 2001, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev., 53, 283
  142. Jain, 1994, Barriers to drug-delivery in solid tumors, Sci. Am., 271, 58, 10.1038/scientificamerican0794-58 · DOI
  143. Jain, 2001, Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function, J. Control. Release, 74, 7, 10.1016/S0168-3659(01)00306-6 · DOI
  144. Jain, 2010, Delivering nanomedicine to solid tumors, Nat. Rev. Clin. Oncol., 7, 653, 10.1038/nrclinonc.2010.139 · DOI
  145. Bramsen, 2009, A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity, Nucleic Acids Res., 37, 2867, 10.1093/nar/gkp106 · DOI · Paper page
  146. Bae, 2011, Targeted drug delivery to tumors: myths, reality and possibility, J. Control. Release, 153, 198, 10.1016/j.jconrel.2011.06.001 · DOI
  147. Khan, 2009, Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs, Nat. Biotechnol., 27, 549, 10.1038/nbt0709-671a · DOI
  148. Murakami, 2011, The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families, PLoS One, 6, e16081, 10.1371/journal.pone.0016081 · DOI
  149. Small, 2010, MicroRNAs add a new dimension to cardiovascular disease, Circulation, 121, 1022, 10.1161/CIRCULATIONAHA.109.889048 · DOI
  150. Das, 2013, Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs, Oncogene, 32, 2927, 10.1038/onc.2012.311 · DOI
  151. Bridge, 2003, Induction of an interferon response by RNAi vectors in mammalian cells, Nat. Genet., 34, 263, 10.1038/ng1173 · DOI
  152. Hornung, 2005, Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7, Nat. Med., 11, 263, 10.1038/nm1191 · DOI
  153. Judge, 2005, Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA, Nat. Biotechnol., 23, 457, 10.1038/nbt1081 · DOI
  154. Sledz, 2003, Activation of the interferon system by short-interfering RNAs, Nat. Cell Biol., 5, 834, 10.1038/ncb1038 · DOI
  155. He, 2007, Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro, Oncogene, 26, 4961, 10.1038/sj.onc.1210307 · DOI
  156. Ong, 2005, Hybrid cytomegalovirus enhancer-h1 promoter-based plasmid and baculovirus vectors mediate effective RNA interference, Hum. Gene Ther., 16, 1404, 10.1089/hum.2005.16.1404 · DOI · Paper page
  157. Samakoglu, 2006, A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference, Nat. Biotechnol., 24, 89, 10.1038/nbt1176 · DOI
  158. Xiang, 2006, Short hairpin RNA-expressing bacteria elicit RNA interference in mammals, Nat. Biotechnol., 24, 697, 10.1038/nbt1211 · DOI
  159. Krichevsky, 2003, 9, 1274
  160. Ling, 2011, The recent updates of therapeutic approaches against A beta for the treatment of Alzheimer's disease, Anat. Rec., 294, 1307, 10.1002/ar.21425 · DOI
  161. Altieri, 2008, Survivin, cancer networks and pathway-directed drug discovery, Nat. Rev. Cancer, 8, 61, 10.1038/nrc2293 · DOI
  162. Wang, 2011, The guideline of the design and validation of MiRNA mimics, Methods Mol. Biol., 676, 211, 10.1007/978-1-60761-863-8_15 · DOI
  163. Sibley, 2010, Novel RNA-based strategies for therapeutic gene silencing, Mol. Ther., 18, 466, 10.1038/mt.2009.306 · DOI
  164. Zhou, 2009, Tumour-initiating cells: challenges and opportunities for anticancer drug discovery, Nat. Rev. Drug Discov., 8, 806, 10.1038/nrd2137 · DOI
  165. Cho, 2012, Exploiting the therapeutic potential of microRNAs in human cancer, Expert Opin. Ther. Targets, 16, 345, 10.1517/14728222.2012.663354 · DOI
  166. Sachdeva, 2010, MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1, Cancer Res., 70, 378, 10.1158/0008-5472.CAN-09-2021 · DOI
  167. Sachdeva, 2011, MicroRNA-101-mediated Akt activation and estrogen-independent growth, Oncogene, 30, 822, 10.1038/onc.2010.463 · DOI
  168. Zhu, 2007, MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1), J. Biol. Chem., 282, 14328, 10.1074/jbc.M611393200 · DOI · Paper page
  169. Zhu, 2008, MicroRNA-21 targets tumor suppressor genes in invasion and metastasis, Cell Res., 18, 350, 10.1038/cr.2008.24 · DOI · Paper page
  170. Nguyen, 2012, Nucleic acid delivery: the missing pieces of the puzzle?, Acc. Chem. Res., 45, 1153, 10.1021/ar3000162 · DOI
  171. Lee, 2009, Silencing by small RNAs is linked to endosomal trafficking, Nat. Cell Biol., 11, 1150, 10.1038/ncb1930 · DOI
  172. Forbes, 2012, Oral delivery of small RNA and DNA, J. Control. Release, 162, 438, 10.1016/j.jconrel.2012.06.037 · DOI

Cited by

Sorted by citations

See all 535

Metadata

Authors
Zhang, Y., Wang, Z., & Gemeinhart, R. A.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2013-12
Volume
172
Issue
3
Pages
962-974
ISSN
0168-3659
DOI
10.1016/j.jconrel.2013.09.015
PMC
PMC3891846
Cited by
535
References
14
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Research Facilities Improvement Program (RR15482)
  • National Centre for Research Resources (NCRR)
  • University of Illinois at Chicago Center
  • NCRR (TR000050)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review